Abstract
Pharmacokinetic and pharmacodynamic properties of gliclazide were studied after an oral administration of gliclazide tablets in healthy volunteers. After an overnight fasting, gliclazide tablet was orally administered to 11 volunteers; Additional 10 volunteers were used as a control group (i.e., no gliclazide administration). Blood samples were collected, and the concentration determined for gliclazide and glucose up to 24 after the administration. Standard pharmacokinetic analysis was carried out for gliclazide. Pharmacodynamic activity of the drug was expressed by increase of glucose concentration (▵APG), by area under the increase of glucose concentration-time curve (AUC▵PG) or by the difference in increase of glucose concentration (D▵PG) at each time between groups with and without gliclazide administration. Pharmacokinetic analysis revealed that Cmax, Tmax, CL/F (apparent clearance), V/F (apparent volume of distribution) and half-life of gliclazide were 4.69±1.38 mg/L, 3.45±1.11 h, 1.26±0.35 L/h, 17.78±5.27 L, and 9.99±2.15 h, respectively. When compared with the no drug administration group, gliclazide decreased significantly the AUC▵PG s at 1, 1.5, 2, 2.5, 3 and 4 h (p<0.05). The ▵PGs were positively correlated with AUCgliclazide at 1 and 1.5 h (p<0.05), and the correlation coefficient was maximum at 1 h (r = 0.642) and gradually decreased at 4 h after the administration. The AUC▵PGs were positively correlated with AUCgliclazide at 1, 2, 3 and 4 h (p<0.05), and the maximum correlation coefficient was obtained at 2 h (r=0.642) after the administration. The D▵PG reached the maximum at 1 h, remained constant from 1 h to 3 h, and decreased afterwards. Therefore, these observations indicated that maximum hypoglycemic effect of gliclazide was reached at approximately at 1.5 h after the administration and the effect decreased, probably because of the homeostasis mechanism, in health volunteers.
Similar content being viewed by others
References
Campbell, D. B., Adrianessens, P., Hopkins, Y. W., Gordon, B., and Williams, J. R. B., Pharmacokinetics and metabolism of gliclazide: G review. In Gliclazide and the Treatment of Diabetes, Keen H. London (ed).Academic Press and the Royal Society of Medicine, 71–82 (1980).
Davis, T. M. E., Daly, F., Walsh, J. P., Ilett, K. F., Beilby, J. P., Dusci, L. J., and Barrett, P. H. R., Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes.Br. J. Clin. Pharmacol., 49, 223–230 (2000).
Glowka, F. K., Hermann, T. W., and Zabel, M., Bioavailablity of gliclazide from some formulation tablets.Int. J. Pharmceut., 172, 71–77 (1998).
Kimura, M., Kobayashi, K., Hata, M., Matsuoka, A., Kitamura, H., and Kimura, Y., Determination of gliclazide in human serum by high-performance liquid chromatography using an anion-exchange resin.J. Chromatogra., 183, 467–473 (1980).
Kobayashi, K., Kimura, M., Sakoguchi, T., Kitani, Y., and Hata, M., Influence of blood protein on biomedical analysis. III. Pharmacokinetics and protein binding of gliclazide.J. Pharmacodyn., 4, 436–442 (1981).
Palmer, K. J. and Brogden, R. N., Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus.Drugs, 46, 92–125 (1993).
Shiba, T., Kajinuma, H., Suzuki, K., Hagura, R., and Kawai, A., Serum gliclazide concentration in diabetic patients. Relationship between gliclazide and serum concentration.Diabetes Res. Clin. Prac., 2, 301–306 (1986).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, H., Yun, M. & Kwon, Ki. Pharmacokinetic and pharmacodynamic characterization of gliclazide in healthy volunteers. Arch Pharm Res 26, 564–568 (2003). https://doi.org/10.1007/BF02976882
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02976882